Dongkook Pharmaceutical will handle domestic distribution of the hyaluronic acid (HA)-based skin booster Inhilo Plus.
Dongkook Pharmaceutical said on the 6th that it signed a domestic licensing agreement for Inhilo with BS Pharm Korea.
Inhilo is an HA-based injectable product approved as a Class IV medical device, a "biomaterial for tissue restoration." It is designed to improve the skin environment by supplying moisture through hyaluronic acid and stimulating fibroblasts to support extracellular matrix (ECM) formation. A dual HA structure that combines low- and high-molecular-weight hyaluronic acid in one syringe (2 mm) is its hallmark.
Through this agreement, Dongkook Pharmaceutical plans to build Inhilo's domestic distribution network and expand its aesthetics product lineup in the aesthetic medical market.